Literature DB >> 19924152

Therapy: evidence-based treatment of Graves ophthalmopathy.

Wilmar M Wiersinga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19924152     DOI： 10.1038/nrendo.2009.222

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.

Authors:  A J Dickinson; P Perros
Journal:  Clin Endocrinol (Oxf)       Date:  2001-09       Impact factor: 3.478

Review 2.  Epidemiology and prevention of Graves' ophthalmopathy.

Authors:  Wilmar M Wiersinga; Luigi Bartalena
Journal:  Thyroid       Date:  2002-10       Impact factor: 6.568

3.  The use of orbital radiotherapy for Graves' ophthalmopathy: quantitative review of the evidence.

Authors:  Rui-Li Wei; Jin-Wei Cheng; Ji-Ping Cai
Journal:  Ophthalmologica       Date:  2007-12-19       Impact factor: 3.250

4.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 5.  Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.

Authors:  Hadas Stiebel-Kalish; Eyal Robenshtok; Murat Hasanreisoglu; David Ezrachi; Ilan Shimon; Leonard Leibovici
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

6.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

7.  Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.

Authors:  Rob J van Geest; Inna V Sasim; Hans P F Koppeschaar; Rachel Kalmann; Simone N Stravers; Ward R Bijlsma; Maarten P Mourits
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

8.  Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.

Authors:  Rosario Le Moli; Lelio Baldeschi; Peerooz Saeed; Noortje Regensburg; Maarten P Mourits; Wilmar M Wiersinga
Journal:  Thyroid       Date:  2007-04       Impact factor: 6.568

9.  The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey.

Authors:  Stephanie Estcourt; Janis Hickey; Petros Perros; Colin Dayan; Bijay Vaidya
Journal:  Eur J Endocrinol       Date:  2009-06-19       Impact factor: 6.664

Review 10.  Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.

Authors:  Elizabeth A Bradley; Emily W Gower; David J Bradley; Dale R Meyer; Kenneth V Cahill; Philip L Custer; David E Holck; John J Woog
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079
  10 in total
  1 in total

1.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.